Wu Guolin, Yu Guoyou, Li Jianping, Xiong Fulin
First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Zhongguo Zhong Yao Za Zhi. 2010 Mar;35(6):782-5.
To investigate short term clinical therapeutic effect of fupiyiwei decoction (FPYWD) combined with chemotherapy in treating postoperational large intestine carcinoma and the effect on immune function.
The 58 cases of postoperational large intestine carcinoma were randomly divided into the traditional Chinese medicine (TCM) group (33 cases) and the control group (25 cases). The toxic and adverse reaction, Karnofsky score and clinical therapeutic effect during chemotherapy were observed, and the level of subgroup of T cells CD3, CD4, CD8 and NK cells were detected. Before and after treatment 28 healthy adult were regarded as normal group.
There was no significant difference in clinic therapeutic effect between the TCM group and the control group after 12 chemotherapy treatment courses. But the quality of life the TCM group remarkably better than in the control group (P < 0.05), while the incidence rate of toxic and adverse reaction of chemotherapy in the former group was lower than in the latter (P < 0.05). The level of CD3+, CD4+ T cell and the viability of NK cells in all patients decreased during the chemotherapy treatment course while the level of CD8+ T cell increased, the level of CD3+ T cell and NK cells in peripheral blood in patients increased after treatment, but was lower than in normal group. The level of CD8+ T cell was decreased and was lower than in normal group. There was no significant difference (P < 0.05). The level of CD4 T cell after TCM group, there was significant different in CD4+ T cell between TCM group and control group, normal group (P < 0.05). The viability of NK cell increased but there was no significant difference between the two group.
Fupiyiwei decoction (FPYWD) is effective in prevention and treatment of the toxic and adverse effects of chemotherapy of postoperational large intestine carcinoma, and can improve quality of life and immune function of patients. increase the effective of chemotherapy.
探讨复脾益胃汤（FPYWD）联合化疗治疗术后大肠癌的近期临床疗效及对免疫功能的影响。
将58例术后大肠癌患者随机分为中药组（33例）和对照组（25例）。观察化疗期间的毒副反应、卡氏评分及临床疗效，并检测T细胞亚群CD3、CD4、CD8及NK细胞水平。将28例健康成年人作为正常组，于治疗前后进行检测。
12个化疗疗程后，中药组与对照组临床疗效无显著差异。但中药组生活质量明显优于对照组（P<0.05），且化疗毒副反应发生率低于对照组（P<0.05）。化疗疗程中所有患者CD3+、CD4+T细胞水平及NK细胞活性降低，CD8+T细胞水平升高；治疗后患者外周血CD3+T细胞及NK细胞水平升高，但低于正常组；CD8+T细胞水平降低，低于正常组，差异无统计学意义（P<0.05）。中药组CD4+T细胞水平与对照组、正常组比较，差异有统计学意义（P<0.05）。NK细胞活性升高，但两组间差异无统计学意义。
复脾益胃汤（FPYWD）可有效防治术后大肠癌化疗的毒副作用，提高患者生活质量及免疫功能，增强化疗疗效。
